Wall Street analysts expect that Cerecor Inc (NASDAQ:CERC) will post earnings of ($0.16) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cerecor’s earnings, with estimates ranging from ($0.18) to ($0.14). Cerecor reported earnings per share of ($0.07) during the same quarter last year, which suggests a negative year over year growth rate of 128.6%. The firm is expected to report its next quarterly earnings results on Friday, May 10th.
According to Zacks, analysts expect that Cerecor will report full-year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($0.77) to ($0.69). For the next financial year, analysts forecast that the firm will post earnings of ($0.76) per share, with EPS estimates ranging from ($0.83) to ($0.64). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Cerecor.
CERC has been the topic of a number of research reports. LADENBURG THALM/SH SH initiated coverage on Cerecor in a research note on Thursday, December 20th. They issued a “buy” rating and a $9.00 price target on the stock. HC Wainwright set a $11.00 price objective on Cerecor and gave the company a “buy” rating in a research report on Wednesday. Maxim Group assumed coverage on Cerecor in a report on Tuesday, April 9th. They issued a “buy” rating and a $10.00 target price on the stock. ValuEngine cut Cerecor from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 7th. Finally, TheStreet raised Cerecor from a “d” rating to a “c-” rating in a research note on Wednesday, January 30th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $10.00.
In other news, Director Armistice Capital, Llc purchased 13,762 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was purchased at an average price of $5.40 per share, for a total transaction of $74,314.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Armistice Capital Master Fund purchased 50,000 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was purchased at an average price of $5.47 per share, with a total value of $273,500.00. The disclosure for this purchase can be found here. Insiders have acquired 577,734 shares of company stock valued at $3,174,301 in the last 90 days. Company insiders own 80.20% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in CERC. Opaleye Management Inc. purchased a new stake in shares of Cerecor in the fourth quarter valued at approximately $6,212,000. Prosight Management LP purchased a new stake in shares of Cerecor in the fourth quarter valued at approximately $994,000. Tibra Equities Europe Ltd purchased a new stake in shares of Cerecor in the first quarter valued at approximately $210,000. Geode Capital Management LLC boosted its holdings in shares of Cerecor by 50.7% in the fourth quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock valued at $306,000 after purchasing an additional 31,951 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Cerecor in the first quarter valued at approximately $109,000. Hedge funds and other institutional investors own 50.26% of the company’s stock.
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.
Further Reading: What is a Candlestick Chart?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.